PetVivo Holdings (PetVivo Holdings) Float Percentage Of Total Shares Outstanding : 76.93% (As of May. 17, 2024)

View and export this data going back to 2012. Start your Free Trial

What is PetVivo Holdings Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, PetVivo Holdings's float shares is 12.90 Mil. PetVivo Holdings's total shares outstanding is 16.77 Mil. PetVivo Holdings's float percentage of total shares outstanding is 76.93%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, PetVivo Holdings's Insider Ownership is 24.33%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, PetVivo Holdings's Institutional Ownership is 0.57%.

PetVivo Holdings Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

PetVivo Holdings's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	12.90	/	16.77
	=	76.93%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PetVivo Holdings (PetVivo Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PetVivo Holdings Inc (OTCPK:PETV) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

5251 Edina Industrial Boulevard, Edina, MN, USA, 55439

Website

https://www.petvivo.com

PetVivo Holdings Inc is an emerging biomedical device company. The group is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for companion animals. A key strategy of the company is to leverage human therapies for the treatment of companion animals cost-effectively and in a timely manner. The accelerated timeline to revenues for veterinary medical devices is a key component of this strategy, which enter the market much earlier than pharmaceuticals and biologics. The product pipeline includes approximately seventeen products intended to treat animals and people. Its patent protection extends to biomaterials, products, production processes, and methods of use provided by the company's portfolio of nineteen patents.

Executives

James Rudolph Martin	director	POBOX 53988, IRVINE CA 92619
A.l. Sarroff Fund, Llc	10 percent owner	43 MEADOW WOODS ROAD, GREAT NECK NY 11020
John Spencer Breithaupt	director	3041 W. PASADENA DR., BOISE ID 83705
Robert J Costantino	director	5805 SEPULVEDA BLVD., SUITE 801, SHERMAN OAKS CA 91411
Joseph William Jasper	director	201 SOUTH 11TH STREET, UNIT 1030, MINNEAPOLIS MN 55403
John Lai	director, 10 percent owner, officer: CEO	12100 SINGLETREE LANE, SUITE 186, EDEN PRAIRIE MN 55344
Robert James Rudelius	director	6913 ARBOR LANE, MCCLEAN VA 22101
Leslie Anne Coolidge	director	345 OLD SUTTON ROAD, BARRINGTON HILLS IL 60010
Robert J. Folkes	officer: Chief Financial Officer	1331 TYLER STREET NE, SUITE 200, MINNEAPOLIS MN 55413
Scott Mitchell Johnson	director	475 LAKESHORE UNIT #32, INCLINE VILLAGE NV 89451
James Joseph Martin	director	4400 BISCAYNE BLVD, SUITE # 670, MIAMI FL 33157
Gregory D Cash	director
John Michael Carruth	officer: Acting Chief Financial Officer	4923 RIVER WOOD DR., SAVAGE MN 55439
Sherry Grisewood	director	377 FAIRMOUNT ROAD, CALIFON NJ 07830
David Don Deming	director	16200 45TH STREET SOUTH, AFTON MN 55001